Immunocore presents ovarian cancer expansion data for IMC-C103C

Immunocore (IMCR) presented data for IMC-C103C, a bispecific T cell engager targeting MAGE-A4, in patients with ovarian cancer. The Phase 1 data, presented in a poster at the ESMO Immuno-Oncology 2022 Congress, include 33 heavily pre-treated patients with ovarian cancer, who received doses of greater than or equal to 90 mcg intravenously. All patients had platinum relapsed/refractory ovarian cancer. The safety profile was consistent with that reported previously and the mechanism of action, i.e., T cell activation. No related AE led to treatment discontinuation or death. At the time of data cut-off, 32 patients were evaluable for response, with one additional patient still on treatment and not having had first tumor assessment. Of the 17 evaluable MAGE-A4 positive patients, one had a durable Partial Response, with a duration of 12.7 months, one patient who had a Stable Disease converted to an unconfirmed PR after the poster data cutoff date and is still ongoing, and 5 had SD. Reductions in ctDNA were observed in over half of ctDNA evaluable patients – 12/22 -, including 7 with greater than or equal to 50% reductions, and even in those with low or zero MAGE-A4 expression. IMC-C103C is part of a co-development / co-promotion collaboration with Genentech, a member of the Roche Group (RHHBY) under which Immunocore shares program costs and profits equally. Both companies are evaluating next steps for the IMC-C103C program